Nowicky Pharma/Ukrainian Anti-Cancer Institute, Austria

Dr. Wassil Nowicky — Dipl. Ing., Dr. techn., DDDr. h. c., Director of “Nowicky Pharma” and

President of the Ukrainian Anti-Cancer Institute (Vienna, Austria). Has finished his study at the

Radiotechnical Faculty of the Technical University of Lviv (Ukraine) with the end of 1955 with

graduation to “Diplomingeniueur” in 1960 which title was nostrificated in Austria in 1975. Inventor

of the anticancer preparation on basis of celandine alkaloids “NSC-631570”. Author of over 300

scientific articles dedicated to cancer research. Dr. Wassil Nowicky is a real member of the New

York Academy of Sciences, member of the European Union for applied immunology and of the

American Association for scientific progress, honorary doctor of the Janka Kupala University in

Hrodno, doctor “honoris causa” of the Open international university on complex medicine in

Colombo, honorary member of the Austrian Society of a name of Albert Schweizer. He has

received the award for merits of National guild of pharmacists of America. the award of Austrian

Society of sanitary, hygiene and public health services and others.

Xeroderma pigmentosum (XP) is a genetic disorder of DNA repair in which the ability to

repair damage caused by ultraviolet (UV) light is deficient. Multiple basal cell carcinomas

(basaliomas) and other skin malignancies frequently occur at a young age in those with XP. In fact,

metastatic malignant melanoma and squamous cell carcinoma are the two most common causes of

death in XP victims. This is a very rare disease. The incidence differs regionally and is between

1:40000 (Japan) and 1:250000 (USA). About 250 XP patients live in the USA, about 50 in

Germany, mostly children. The life expectance is low; usually they die in the first decade. If left

unchecked, damage caused by UV light can cause mutations in individual cells DNA. XP patients

are at a high risk (more than 2000 times over the general population) for developing skin cancers,

such as basal cell carcinoma, for this reason. A report on the successful using NSC-631570 in a XP

patient suggests this drug can be very useful also in this hereditary disease.

Patient S.S., an eight year old boy, was presented with an ulcering lesion of the nose. As he

was 10 month old, xeroderma pigmentosum was diagnosed. Until the age of three years the number

of skin lesions increased considerably. In May 2002 skin cancer (squamous cell carcinoma) at the

nose was diagnosed, T4NXM0, histologically verified. From May till June 2002 three cycles of

chemotherapy were administered (cyclophosphamide, vincristine, and vinblastine). The therapy

failed and the tumors grew up. Clinical investigation in April 2004 revealed deforming malignant

melanoma of the nose with invasion into the cartilage of nasal septum, measuring 3x3 cm. On 20

May 2004 the therapy with Ukrain was started, 5 mg intravenously twice a week, up to a total dose

of 85 mg. One month after the last administration of Ukrain a complete regression of the tumor was

revealed. The skin defect was partially replaced with connective tissue. Xeroderma skin lesions

improved throughout the body.

Adolescent Health & Medicine